Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

AstraZeneca Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (113)
Cancellation by sponsor (63)
Australian Public Assessment Report (AusPAR) (44)
Prescription medicine registration (42)
Designation or determination (21)
Prescription medicine evaluation (15)
Prescription medicine decision summary (11)
Section 14, TGO91 consent (1)

Date

2024 (37)
2023 (32)
2022 (45)
2021 (25)
2020 (16)
2019 (20)
2018 (19)
2017 (14)
2016 (11)
2015 (14)
2014 (13)
2013 (10)
2012 (3)
2011 (6)
2010 (4)
2008 (3)
2007 (1)
2006 (8)
2004 (2)
2003 (5)
2002 (3)
2001 (2)
1997 (2)
1996 (3)
1991 (12)

Results for "[search-keyword]"

Search

Sponsor content

310 result(s) found, displaying 171 to 180

PULMICORT Respules budesonide 0.125mg/mL nebuliser suspension (297787)

19 December 2017

ARTG

Australian Register of Therapeutic Goods (ARTG) information for PULMICORT Respules budesonide 0.125mg/mL nebuliser suspension.
Calquence

13 December 2019

Prescription medicine decision summary

Australian prescription medicine decision summary
CALQUENCE (AstraZeneca Pty Ltd)

22 November 2019

Prescription medicine registration

Active ingredients: acalabrutinib.
CALQUENCE (AstraZeneca Pty Ltd)

21 November 2019

Prescription medicine registration

Active ingredients: acalabrutinib.
AusPAR: Olaparib

16 October 2019

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Olaparib
Notice for moxetumomab pasudotox (AstraZeneca Pty Ltd)

25 September 2019

Designation or determination

Orphan drug
AusPAR: Osimertinib mesilate

1 August 2019

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Osimertinib mesilate
ASTRAZENECA WATER FOR INJECTIONS 2mL ampoule Cancelled under Section 30(1)(c) of the Act

7 August 2019

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
ASTRAZENECA SODIUM CHLORIDE 0.9% 5mL injection BP ampoule Cancelled under Section 30(1)(c) of the Act

7 August 2019

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
ASTRAZENECA SODIUM CHLORIDE 0.9% 10mL injection BP ampoule Cancelled under Section 30(1)(c) of the Act

7 August 2019

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd

Pages

First page
Previous page
…
Page 14
Page 15
Page 16
Page 17
Current page 18
Page 19
Page 20
Page 21
Page 22
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.